179 related articles for article (PubMed ID: 38237141)
1. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Abdelrazak Morsy MH; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
Blood; 2024 May; 143(19):1953-1964. PubMed ID: 38237141
[TBL] [Abstract][Full Text] [Related]
2. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Morsy MHA; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
Blood; 2024 Jan; 143(19):1953-1964. PubMed ID: 38774451
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma.
Merrien M; Wasik AM; Ljung E; Morsy MHA; de Matos Rodrigues J; Carlsten M; Rassidakis GZ; Christensson B; Kolstad A; Jerkeman M; Ek S; Herold N; Wahlin BE; Sander B
Virchows Arch; 2022 Mar; 480(3):655-666. PubMed ID: 34738194
[TBL] [Abstract][Full Text] [Related]
4. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
[TBL] [Abstract][Full Text] [Related]
5. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.
Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CB; Sandhow L; Kutzner J; Hed Myrberg I; Bunten SS; Axelsson H; Zhang SM; Rasti A; Mäkelä P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtiö J; Rassidakis GZ; Pokrovskaja Tamm K; Warpman-Berglund U; Heyman M; Grandér D; Lehmann S; Lundbäck T; Qian H; Henter JI; Schaller T; Helleday T; Herold N
EMBO Mol Med; 2020 Mar; 12(3):e10419. PubMed ID: 31950591
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma.
Wang X; Björklund S; Wasik AM; Grandien A; Andersson P; Kimby E; Dahlman-Wright K; Zhao C; Christensson B; Sander B
PLoS One; 2010 Nov; 5(11):e14085. PubMed ID: 21124928
[TBL] [Abstract][Full Text] [Related]
8. MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11.
Wu B; Li J; Wang H; Wu Q; Liu H
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2197-2208. PubMed ID: 32040593
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML.
Zhang F; Sun J; Tang X; Liang Y; Jiao Q; Yu B; Dai Z; Yuan X; Li J; Yan J; Zhang Z; Fan S; Wang M; Hu H; Zhang C; Lv XB
Cell Death Dis; 2022 Jul; 13(7):590. PubMed ID: 35803902
[TBL] [Abstract][Full Text] [Related]
10. SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression.
Wasik AM; Lord M; Wang X; Zong F; Andersson P; Kimby E; Christensson B; Karimi M; Sander B
Sci Rep; 2013; 3():1400. PubMed ID: 23466598
[TBL] [Abstract][Full Text] [Related]
11. High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma.
Kuo PY; Leshchenko VV; Fazzari MJ; Perumal D; Gellen T; He T; Iqbal J; Baumgartner-Wennerholm S; Nygren L; Zhang F; Zhang W; Suh KS; Goy A; Yang DT; Chan WC; Kahl BS; Verma AK; Gascoyne RD; Kimby E; Sander B; Ye BH; Melnick AM; Parekh S
Oncogene; 2015 Mar; 34(10):1231-40. PubMed ID: 24681958
[TBL] [Abstract][Full Text] [Related]
12. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
13. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
Balsas P; Palomero J; Eguileor Á; Rodríguez ML; Vegliante MC; Planas-Rigol E; Sureda-Gómez M; Cid MC; Campo E; Amador V
Blood; 2017 Jul; 130(4):501-513. PubMed ID: 28533307
[TBL] [Abstract][Full Text] [Related]
14. [Relationship of Expression Between SOX11 and PAX5 in Pathological Tissue Specimens of Patients with Mantle Cell Lymphoma and Its Clinical Significance].
Jing CX; Feng Y; Cao X; Xu CG
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):355-360. PubMed ID: 32543142
[TBL] [Abstract][Full Text] [Related]
15. SOX11, a key oncogenic factor in mantle cell lymphoma.
Beekman R; Amador V; Campo E
Curr Opin Hematol; 2018 Jul; 25(4):299-306. PubMed ID: 29738333
[TBL] [Abstract][Full Text] [Related]
16. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.
Mohanty A; Sandoval N; Phan A; Nguyen TV; Chen RW; Budde E; Mei M; Popplewell L; Pham LV; Kwak LW; Weisenburger DD; Rosen ST; Chan WC; Müschen M; Ngo VN
Blood; 2019 Jan; 133(4):306-318. PubMed ID: 30530749
[TBL] [Abstract][Full Text] [Related]
17. SOX11 augments BCR signaling to drive MCL-like tumor development.
Kuo PY; Jatiani SS; Rahman AH; Edwards D; Jiang Z; Ahr K; Perumal D; Leshchenko VV; Brody J; Shaknovich R; Ye BH; Parekh S
Blood; 2018 May; 131(20):2247-2255. PubMed ID: 29615403
[TBL] [Abstract][Full Text] [Related]
18. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.
Vegliante MC; Palomero J; Pérez-Galán P; Roué G; Castellano G; Navarro A; Clot G; Moros A; Suárez-Cisneros H; Beà S; Hernández L; Enjuanes A; Jares P; Villamor N; Colomer D; Martín-Subero JI; Campo E; Amador V
Blood; 2013 Mar; 121(12):2175-85. PubMed ID: 23321250
[TBL] [Abstract][Full Text] [Related]
19. Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma.
Emruli VK; Olsson R; Ek F; Ek S
BMC Cancer; 2016 Jul; 16():493. PubMed ID: 27430213
[TBL] [Abstract][Full Text] [Related]
20. Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo.
Conrotto P; Andréasson U; Kuci V; Borrebaeck CA; Ek S
Mol Oncol; 2011 Dec; 5(6):527-37. PubMed ID: 21880559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
